No Data
No Data
J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45
Express News | Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $45 From $44
Edgewise Therapeutics Insider Sold Shares Worth $276,776, According to a Recent SEC Filing
Insider Sale: CMO of $EWTX Sells 25,000 Shares
Edgewise Rated as a New Hold at Stifel on a Balanced Risk-reward Setup
Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall